P2X7受体在肿瘤发生发展中的作用研究进展  

Recent Advances in the Involvement of P2X7 Receptors in Tumors

作　　者：姚佳宝 于烨 YAO Jiabao;YU Ye(Schools of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学基础医学与临床药学学院,江苏南京211198

出　　处：《生物化工》2024年第4期183-193,共11页Biological Chemical Engineering

基　　金：中央高校基本科研业务费专项资金资助项目(2632023TD10);2021年湖湘高层次人才聚集工程-创新人才(2021RC5013)。

摘　　要：P2X7受体(P2X7 Purinergic Receptor,P2X7R)是一种非选择性三聚体阳离子通道,受胞外ATP激活而开放。其具有对三磷酸腺苷(Adenosine Triphosphate,ATP)亲和力较低、不易脱敏及大孔开放等特征。P2X7R广泛表达于肿瘤细胞和免疫细胞中,被认为与肿瘤密切相关,是潜在的抗肿瘤药物靶点。多数观点认为P2X7R在肿瘤中的表达上调,其抑制剂可以抑制肿瘤发生发展,但由于P2X7R对肿瘤微环境(Tumor Microenvironment,TME)尤其是TME中的免疫细胞会产生复杂影响,导致P2X7R抑制剂临床研究进展缓慢。本文主要从P2X7R对肿瘤以及TME产生的影响入手,总结了近年来的研究进展。The P2X7 purinergic receptor is a non-selective trimer cation channel that is open by extracellular ATP activation.It has characteristics such as low affinity for adenosine triphosphate(ATP),difficulty in desensitization,and macropore opening.P2X7R is widely expressed in immune and tumor cells,and it is thought to be strongly associated with cancers and a possible target for anti-tumor drugs.Most opinions believe that P2X7R is up-regulated in tumors,and its inhibitors can inhibit the development of tumors.However,due to the complex effects of P2X7R on tumor microenvironment(TME),especially immune cells in TME,clinical research on P2X7R inhibitors has progressed slowly.This work focuses on P2X7R' s impacts on tumors and TME,summarizing recent research findings.

关 键 词：P2X7受体 三磷酸腺苷 肿瘤 肿瘤微环境 

分 类 号：R730.2[医药卫生—肿瘤]